DGAP-News: WILEX AG starts clinical phase I trial with PI3K inhibitor WX-037
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Study
WILEX AG starts clinical phase I trial with PI3K inhibitor WX-037
07.08.2013 / 07:05
---------------------------------------------------------------------
PRESS RELEASE
WILEX starts clinical phase I trial with PI3K inhibitor WX-037
Munich, 07 August 2013. WILEX AG (ISIN DE0006614720 / WL6 / FWB) today
announced that the first patients were enrolled and dosed in a clinical
phase I trial with the PI3K inhibitor WX-037. The open-label,
dose-escalation study is being conducted in patients with solid tumours in
three study centres in the UK.
The purpose of the trial is to investigate the safety, pharmacokinetics,
pharmacodynamics and clinical activity of the PI3K inhibitor as monotherapy
as well as in combination with the MEK inhibitor WX-554. In the first part,
patients with advanced solid tumours, for whom there is no effective
standard therapy available, will be given WX-037. In the second part of the
trial, patients with a deregulated PI3K pathway will be treated with WX-037
in combination with WX-554. According to the study design, treatment cycles
of three weeks until toxicity or tumour progression are planned.
More information can be found at www.ClinicalTrials.gov, Identifier:
NCT01859351.
About WX-037
The phosphatidylinositol-3-kinase/protein-kinase signalling pathway - PI3K
in short - sends a 'growth' signal to the nucleus of a tumour cell. It has
been shown that abnormal mutations of the PI3K signalling pathway are
present in most types of cancer.
The PI3K inhibitor was acquired from UCB for further development in 2009
under the terms of a strategic alliance. Since then several preclinical
trials concerning toxicology, pharmacology and pharmacokinetics have been
conducted and the process for producing WX-037 in capsule form has been
developed.
With the WX-037 project, WILEX AG is participating in the m4 Personalised
Medicine and Targeted Therapies initiative of the Munich-based m4 Biotech
Cluster, prize winners of the 'Leading-Edge Cluster' competition run by the
Federal Ministry of Education and Research (BMBF). WILEX receives total
funding of up to EUR 2.6 million from the BMBF for the preclinical and
clinical development of the PI3K inhibitor
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company has a broad portfolio of diagnostic and
therapeutic products for the specific detection and targeted treatment of
various types of cancer. WILEX's therapeutic product candidates are based
on antibodies (RENCAREX(R) in Phase III) and small molecules (MESUPRON(R)
two Phase IIa trials completed, WX-554 in Phase Ib/II and WX-037 in
preclinical development). In the field of diagnostics, REDECTANE(R) is an
antibody-based, imaging diagnostic agent that is currently in a Phase III
programme. WILEX's US subsidiary WILEX Inc. in Cambridge, MA, markets a
portfolio of research use only tests and in vitro diagnostic agents under
the brand Oncogene Science. The subsidiary Heidelberg Pharma GmbH offers an
attractive and highly promising antibody drug conjugate technology platform
and preclinical contract research services. The business model of WILEX
comprises research, technology, product development and commercialisation.
WILEX's customers and partners include leading international pharmaceutical
companies.
Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6
Contact
WILEX AG
Katja Arnold (CIRO)
Grillparzerstrasse 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors(at)wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
07.08.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
224527 07.08.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.08.2013 - 07:05 Uhr
Sprache: Deutsch
News-ID 285306
Anzahl Zeichen: 19982
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG starts clinical phase I trial with PI3K inhibitor WX-037"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
